Alberta Health Services

Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme.

Canadian researchers have successfully developed a one-time gene therapy treatment for Fabry disease that restored enzyme production to near-normal levels in all five trial participants within one week.